Sumanta Kumar Pal, MD

Articles

Dr. Pal on the Sequencing of Immunotherapy for Urothelial Carcinoma

October 18th 2017

Sumanta Kumar Pal, MD, co-director of the Kidney Cancer Program at the City of Hope, discusses the sequencing of immunotherapy regimens in patients with urothelial carcinoma.

Dr. Pal on the CheckMate-214 and CABOSUN Studies in RCC

October 13th 2017

Sumanta Kumar Pal, MD, co-director of the Kidney Cancer Program at the City of Hope in Duarte, California, discusses the CheckMate-214 and CABOSUN trials for patients with renal cell carcinoma (RCC).

Dr. Pal on Preoperative Immunotherapy in Patients With RCC

January 24th 2017

Sumanta Kumar Pal, MD, medical oncologist, assistant clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, City of Hope, discusses the potential with immunotherapy in the preoperative setting for patients with renal cell carcinoma.

Dr. Pal on Sequencing Challenges for the Treatment of Patients With RCC

November 3rd 2016

Sumanta Kumar Pal, MD, medical oncologist, assistant clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope, discusses the challenges with sequencing the therapies available for patients with renal cell carcinoma (RCC). Pal shared this insight in an interview during the 2016 OncLive State of the Science Summit on GU Cancer.

Dr. Pal on Biomarker Development in Renal Cell Carcinoma

July 15th 2016

Sumanta Kumar Pal, MD, assistant clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, City of Hope, discusses biomarker development in the field of renal cell carcinoma (RCC).

Dr. Pal on Sequencing Abiraterone and Enzalutamide in mCRPC

April 23rd 2014

Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses the results of a retrospective analysis of the effect of prior abiraterone use on the activity level of enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Pal on RCS in Metastatic Urothelial Carcinoma

January 31st 2014

Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses changes in relative conditional survival in metastatic urothelial carcinoma.

Dr. Pal on Sequencing Nivolumab in RCC

December 2nd 2013

Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses sequencing nivolumab in the treatment of renal cell carcinoma.

Dr. Pal on Adjuvant Therapy of Renal Cell Carcinoma

November 13th 2013

Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses adjuvant therapy of renal cell carcinoma (RCC).